Aytu BioScience, Inc

Short Term Long Term Short Term Comparison Long Term Comparison
  • AYTU
  • 1d-7.26%
  • 1w-20.24%
  • 1m-6.62%
  • 1y5.10%
ATH
  • ATH Price$1,000,000.00
  • ATH Date2008-09-24
  • % since ATH-100.00%
  • % to ATH37,313,332.84%
ATL
  • ATL Price$1.49
  • ATL Date2023-06-28
  • % from ATL79.87%
  • Last Low Price$1.49
  • Last Low Date2023-06-28
  • % From Last Low79.87%
IPO
  • IPO Price$0.25
  • % Current ROI USD1,072.00%
  • ATH Price$1,000,000.00
  • % ROI ATH 6,711,409,395.97%
Share

Graph takes few seconds to load...

Key Data
Share

Current price $2.68
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Today's High/Low $2.86/$2.65
Volume 55,646.00
Previous Close $2.8899
52 Week High/Low $3.5/$1.38
Market Cap 15,868,217.00
P/E Ratio 0
Forward P/E 1 Yr. $5.78
Earnings Per Share(EPS) $0.5
Annualized Dividend $0
$2.68
Share

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally.
The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension.
It also offers ZolpiMist, an oral spray for the treatment of insomnia; and MiOXSYS, an in vitro diagnostic semen analysis test that is used in the measurement of static oxidation reduction potential in human semen.
The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Englewood, Colorado.

Annual Data | Millions of US $ except per share data
Cash on hand
Receivables
Inventory
Pre-Paid Expenses
Other Current Assets
Total Current Assets
Property, Plant, And Equipment
Long-Term Investments
Goodwill And Intangible Assets
Other Long-Term Assets
Total Long-Term Assets
Total Assets
Total Current Liabilities
Long Term Debt
Other Non-Current Liabilities
Total Long Term Liabilities
Total Liabilities
Common Stock Net
Retained Earnings (Accumulated Deficit)
Comprehensive Income
Other Share Holders Equity
Share Holder Equity
Total Liabilities And Share Holders Equity